Last reviewed · How we verify
UB-VV410
At a glance
| Generic name | UB-VV410 |
|---|---|
| Sponsor | Nanjing IASO Biotechnology Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- UB-VV410 CI brief — competitive landscape report
- UB-VV410 updates RSS · CI watch RSS
- Nanjing IASO Biotechnology Co., Ltd. portfolio CI